| Literature DB >> 24523574 |
Monika Ryba-Stanisławowska1, Karolina Rybarczyk-Kapturska1, Agnieszka Brandt2, Małgorzata Myśliwiec2, Jolanta Myśliwska1.
Abstract
PURPOSE: The study aimed to investigate the influence of estrogen receptor α (ER-α) genotypes on inflammatory response and development of microvascular complications in girls with type 1 diabetes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24523574 PMCID: PMC3910071 DOI: 10.1155/2014/839585
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Clinical characteristics of girls with type 1 diabetes differing in the IVS1 −397T>C estrogen receptor α polymorphism.
| Clinical parameter | CC | CT | TT |
|
|
|
|
|---|---|---|---|---|---|---|---|
|
| 37 | 70 | 45 | ||||
| Age (years) | 14.2 ± 3.4 | 14.0 ± 3.6 | 13.2 ± 3.8 | 0.81 | 0.86 | 0.79 | 0.74 |
| Duration of diabetes (years) | 5.3 ± 3.3 | 4.1 ± 3.1 | 4.6 ± 3.8 | 0.53 | 0.09 | 0.58 | 0.36 |
| BMI (kg/m2) | 20.1 ± 3.5 | 19.4 ± 3.6 | 18.7 ± 3.8 | 0.05 | 0.28 | 0.39 |
|
| HbA1c (%) | 8.9 ± 2.5 | 8.6 ± 2.1 | 9.2 ± 2.4 | 0.21 | 0.28 | 0.17 | 0.67 |
| CRP (mg/mL) | 1.6 ± 1.4 | 1.8 ± 1.6 | 2.5 ± 2.3 | 0.1 | 0.5 | 0.06 |
|
| Albumin excretion rate (mg/24 h) | 19.8 ± 16.2 | 20.8 ± 19.4 | 23.3 ± 22.6 | 0.6 | 0.39 | 0.08 | 0.37 |
| Serum creatinine level (mg/dL) | 0.75 ± 0.13 | 0.74 ± 0.17 | 0.73 ± 0.16 | 0.98 | 0.33 | 0.34 | 0.61 |
Differences were calculated by the Kruskal-Wallis ANOVA test. Data are presented as mean ± SD.
P: the comparison between three analyzed genotypes CC, CT, and TT.
P*: post hoc comparison between patients bearing CC and CT genotypes.
P**: post hoc comparison between patients bearing CT and TT genotypes.
P***: post hoc comparison between patients bearing CC and TT genotypes.
Serum level of 17β-estradiol in DM1 and healthy young girls differing in the IVS1 −397T>C estrogen receptor α polymorphism.
| CC | CT | TT |
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Control group | 217 ± 59 | 234.6 ± 152.9 | 220.1 ± 74.3 | 0.86 | 0.8 | 0.69 | 0.89 |
| DM1 | 281.1 ± 262.6 | 248.3 ± 130.3 | 141.4 ± 75.5 |
| 0.28 | 0.06 |
|
Differences were calculated by the Kruskal-Wallis ANOVA test. Data are presented as mean ± SD.
The values are presented as pmol/L.
P: the comparison between three analyzed genotypes CC, CT and TT.
P*: post hoc comparison between patients bearing CC and CT genotypes.
P**: post hoc comparison between patients bearing CT and TT genotypes.
P***: post hoc comparison between patients bearing CC and TT genotypes.
Flow cytometric analysis of CD4+IL17A+ T cells in girls differing in the IVS1 −397T>C estrogen receptor α polymorphism.
| CC | CT | TT |
|
|
|
| |
|---|---|---|---|---|---|---|---|
| CD4+IL17A+ T cells (%) | |||||||
| Control group | 1.1 (0.9/1.4) | 0.9 (0.7/1.3) | 1.2 (0.8/1.5) | 0.4 | 0.42 | 0.29 | 0.68 |
| DM1 | 1.5 (1.1/2.1) | 2.1 (1.5/3.25) | 2.69 (2.04/3.7) | 0.18 | 0.09 | 0.95 |
|
PBMCs from type 1 diabetic (DM1) and healthy (control group) girls were cultured and stimulated as described in Section 2 and then stained with antibodies against CD4 and IL17A. The percentage of CD4+IL17A+ T cells was determined by flow cytometry. Analyzing CD4+IL17A+ cells, dot plots representing anti-CD4 versus SS were carried out to establish CD4+ and CD4− lymphocyte gates. Then, the anti-CD4 versus IL17A from CD4+ gate dot plot was generated and the frequency of Th17 cells was determined.
Results are shown as median and 10./90. percentile. Differences were calculated by the Kruskal-Wallis ANOVA test.
P: the comparison between three analyzed genotypes CC, CT, and TT.
P*: post hoc comparison between patients bearing CC and CT genotypes.
P**: post hoc comparison between patients bearing CT and TT genotypes.
P***: post hoc comparison between patients bearing CC and TT genotypes.
The level of serum cytokines in analyzed subjects.
| DM1 girls with coexisting microvascular complications ( | DM1 girls free from microvascular complications ( | Control group ( |
|
|
|
| |
|---|---|---|---|---|---|---|---|
| IL-6 (pg/mL) | 0.9 (0.4/1.8) | 0.8 (0.2/1.5) | 0.4 (0.2/0.6) |
| 0.34 |
| < |
| TNF- | 1.8 (1.1/2.8) | 0.0 (0/0.8) | 0.0 (0/0) | < | < |
| < |
| VEGF (pg/mL) | 216.8 (57.4/439.3) | 98.4 (43.6/181.1) | 113.4 (29.6/289.7) |
|
| 0.17 | 0.05 |
| IL-10 (pg/mL) | 0.5 (0/1.4) | 0.6 (0.1/1.8) | 0 (0/1.5) | 0.44 | 0.14 |
| 0.64 |
Data are presented as median and 10./90. percentile. Differences were calculated by the Kruskal-Wallis ANOVA test and post hoc NIR test.
P: comparison between three analyzed subject groups.
P*: post hoc comparison between DM1 girls with complications and DM1 group without complications.
P**: post hoc comparison between DM1 girls without complications and the control group.
P***: post hoc comparison between DM1 girls with complications and the control group.
Figure 1Serum levels of IL-6, TNF-α, VEGF, and IL-10 in DM1 girls differing in the IVS1 −397T>C polymorphism. In DM1 group the value of serum cytokines was measured by ELISA and analyzed according to different genetic variants of the IVS1 –397T>C estrogen receptor α polymorphism. (a) The mean value (25/75 percentiles) of IL-6 was 0.48 (0.03/1.5), 0.7 (0.3/1.84), and 1.39 (0.7/2.157) pg/mL for CC, CT, and TT, respectively. (b) The mean value (25/75 percentiles) of TNF-α was 0.6 (0.15/1), 1 (0.2/2), and 1.4 (0.5/2.4) pg/mL for CC, CT, and TT, respectively. (c) The mean value (25/75 percentiles) of VEGF was 76.89 (36.28/128.39), 128.45 (43.89/227.04), and 221.1 (57.4/382.76) pg/mL for CC, CT, and TT, respectively. (d) The mean value (25/75 percentiles) of IL-10 was 1.2 (0.3/2.2), 0.6 (0.0/1.7), and 0.5 (0.0/1.1) pg/mL for CC, CT, and TT, respectively. Differences were calculated by the Kruskal-Wallis ANOVA test and the post hoc NIR test.
The results of the correlation analysis between serum level of 17β-estradiol, Th17 subset, and the concentrations of analyzed cytokines in DM1 patients.
| IL-6 | TNF- | VEGF | IL-10 | |
|---|---|---|---|---|
| Serum level of 17 |
|
|
|
|
|
|
|
|
| |
| The percentage of CD4+IL17A+ T cells (%)* |
|
|
|
|
|
|
|
|
|
The Spearman test was used to calculate the strength of correlation.
*The percentage of cells among peripheral blood lymphocytes.
(a)
| Girls with DM1
| Girls with DM1 and nephropathy
| Girls with DM1 without nephropathy
| |
|---|---|---|---|
| CC | 37 (24.3) | 4 (14.3) | 33 (26.8) |
| CT | 70 (46.1) | 14 (50) | 56 (45.5) |
| TT | 45 (29.6) | 10 (35.7) | 34 (27.6) |
|
| — | 2.07; | |
|
| — | 2.25; | |
Data were calculated with χ 2 Pearson's test.
n: number of patients.
(b)
| Girls with DM1
| Girls with DM1 and retinopathy | Girls with DM1 without retinopathy | |
|---|---|---|---|
| CC | 37 (24.3) | 2 (9.5) | 35 (26.9) |
| CT | 70 (46.1) | 8 (38.1) | 62 (47.7) |
| TT | 45 (29.6) | 11 (52.4) | 33 (25.4) |
|
| — | 7.11; | |
|
| — | 6.99; | |
Data were calculated with χ 2 Pearson's test.
n: number of patients.